Shields Anthony F
Karmanos Cancer Institute, Department of Medicine, Wayne State University, 4100 John R Street 4HWCRC, Detroit, MI 48201-2013, USA.
Mol Imaging Biol. 2006 May-Jun;8(3):141-50. doi: 10.1007/s11307-006-0039-2.
This work highlights the explosion and evolution of positron emission tomography (PET) for use in oncology research and clinical practice. 2-Deoxy-2-[F-18]fluoro-D-glucose (FDG)-PET is important in the staging of cancer, estimation of prognosis, and for its ability to predict therapeutic outcome. A number of new imaging agents are under development and may find a place in oncology when studies prove their utility. This scientific overview includes a review of the development of a number of thymidine analogs, such as 18F-3'-deoxy-3'-fluorothymidine (FLT) and 18F-1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-thymine (FMAU), including chemical structure variations; their application in a variety of tumors; and the role of various kinetic models for understanding cellular proliferation. The greatest unmet need for PET is in further developing and validating its use in the measurement of treatment response.
这项工作突出了正电子发射断层扫描（PET）在肿瘤学研究和临床实践中的迅猛发展与演变。2-脱氧-2-[F-18]氟-D-葡萄糖（FDG）-PET在癌症分期、预后评估以及预测治疗结果的能力方面具有重要意义。一些新型成像剂正在研发中，当研究证明其效用时，可能会在肿瘤学领域占据一席之地。这篇科学综述包括对多种胸苷类似物的发展回顾，如18F-3'-脱氧-3'-氟胸苷（FLT）和18F-1-(2'-脱氧-2'-氟-β-D-阿拉伯呋喃糖基)-胸腺嘧啶（FMAU），涵盖化学结构变化；它们在多种肿瘤中的应用；以及各种动力学模型在理解细胞增殖中的作用。PET尚未满足的最大需求在于进一步开发并验证其在治疗反应测量中的应用。
